Advancing Knowledge on Adenoviral Conjunctivitis (Pink Eye)

Why is this study needed?

There is no U.S. Food and Drug Administration (FDA) approved treatment for “pink eye”.  Standard care recommended by the American Academy of Optometry and American Ophthalmology Academy is with artificial tears to relieve symptoms and to possibly reduce adenovirus in the eye.  Another possible treatment is with Betadine 5%, an antiseptic ophthalmic solution used for over 50 years to prepare patient’s eye and surrounding area for eye surgery and to clean minor wounds.  Because Betadine 5% kills bacteria and viruses, it may be useful in treating adenoviral conjunctivitis.  This study will be among the first to test Betadine 5% for “pink eye”.


Adenoviral conjunctivitis is highly contagious. It can easily spread to the other eye, to co-workers and family members or spread by touching contaminated surfaces e.g. door handles, elevator buttons or keyboards.

About the Study

Patients are randomized to receive either one in‐office administration of 5% Betadine, or artificial tears (control) at baseline and are managed per standard of care with artificial tears 4 times/day until resolution of symptoms. Follow-up visits are 1‐2, 4, 7, 14 and up to 21 days.

Each follow-up visit is about 30 minutes and you will be asked to:

  • Complete a questionnaire about symptoms.
  • Receive a comprehensive eye examination.
  • Give a sample of tears to measure adenovirus levels.
  • Receive a $20 Gift Card for each follow-up visit.

How Can I Participate?

  • Are you 18 years of age or older?
  • Have you had symptoms for 4 days or less?
  • Search for a Clinical Center in your area